Synlogic

Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.

The World Health Organization has approved “labafenogene marselecobac” Name attributes recognize Synlogic's proprietary technology  and commitment to phenylketonuria community CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has selected "labafenogene marselecobac" for the nonproprietary name of the company's investigational drug for phenylketonuria (PKU), previously known as SYNB1934.

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

CAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that its management team will participate in the SVB Securities Healthcare Therapeutics Forum, being held in New York, July 11-12, 2023. The Synlogic team will be available for one-on-one investor meetings. To register for the conference or request one-on-one meetings, please contact your SVB Securities representative.

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST. The Annual Meeting will be held in a virtual meeting format only.

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in rare metabolic diseases CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU).

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held May 30 – June 2, 2023 in Los Angeles, CA. The company's oral presentation focuses on Synlogic's development of a Synthetic Biotic drug candidate for the potential treatment of homocystinuria (HCU), a rare metabolic disease caused by an inborn error of metabolism. The company's poster presentations highlight preclinical and clinical data. Presentation details are provided below.

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference being held in New York, NY, June 7-9, 2023.

Synlogic to Present at the Jefferies Global Healthcare Conference

Alzamend Neuro

eFFECTOR Therapeutics Inc

Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.

3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year

Synlogic, Inc. (SYBX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.22 per share a year ago.

Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates

- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orphan designation from the EMA for SYNB1934 as a potential treatment for PKU - CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the first quarter ended March 31, 2023, and provided an update on its pipeline programs.

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for

C3.ai

Solid Power

Megatrends exist across many thematic areas of the stock market. Identifying these trends usually involves analyzing key factors such as technological breakthroughs, social change, urbanization, climate change, and global wealth shifts and capitalizing on them.

3 Megatrend Stocks to Buy for 10x Potential Returns

Avalo Therapeutics

Oric Pharmaceuticals

Twist Bioscience Corp

Exact Sciences

INmune Bio Inc

Tenaya Therapeutic

Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person's body.

The 7 Best Biotech Stocks for Personalized Medicine Investors

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 –

Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company's application for orphan designation for SYNB1934 for the treatment of phenylketonuria (PKU).

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuria Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuria

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

– Podium presentation on Phase 2 phenylketonuria (PKU) data –

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced it will participate in the following upcoming investor and industry conferences:

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for the potential treatment of phenylketonuria (PKU).

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why

Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023

Synlogic Provides Corporate Update and Outlook for 2023

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023.

Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract

News for Synlogic Stock (SYBX)